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Abstract 33 
To our knowledge, no study has evaluated the involvement of T helper (Th)1- and Th2-34 
chemokines in extra-ocular muscle (EOM) myopathy in “patients with thyroid-associated 35 
ophthalmopathy” (TAO-p). 36 
We tested the effects of interferon (IFN)γ and tumor necrosis factor (TNF)α stimulation, and 37 
of increasing concentrations of peroxisome proliferator-activated receptor (PPAR)γ agonists 38 
(pioglitazone or rosiglitazone; 0.1 µM-20 µM), on Th1-chemokine [C-X-C motif ligand 39 
(CXCL)10] and Th2-chemokine [C-C motif ligand (CCL)2] secretion in primary EOM 40 
cultures from TAO-p vs. control myoblasts. Moreover, we evaluated serum CXCL10 and 41 
CCL2 in active TAO-p with prevalent EOM involvement (EOM-p) vs. those with prevalent 42 
orbital fat expansion (OF-p).  43 
Serum CXCL10 was higher in OF-p and EOM-p vs. controls, while serum CCL2 was not 44 
significantly different in controls, or in OF-p and EOM-p. We showed the expression of 45 
PPARγ in EOM cells. In primary EOM cultures from TAO-p: a) CXCL10 was undetectable 46 
in the supernatant, IFNγ dose-dependently induced it, whereas TNFα did not; b) EOM 47 
produced basally low amounts of CCL2, TNFα dose-dependently induced it, whereas IFNγ 48 
did not; c) the combination of TNFα and IFNγ had a significant synergistic effect on 49 
CXCL10 and CCL2 secretion; d) PPARγ agonists have an inhibitory role on the modulation 50 
of CXCL10, while stimulated CCL2 secretion. 51 
EOM participate in the self-perpetuation of inflammation by releasing both Th1 (CXCL10) 52 
and Th2 (CCL2) chemokines under the influence of cytokines, in TAO. PPARγ agonists 53 
activation plays an inhibitory role on CXCL10, but stimulates the release of CCL2. 54 
 55 
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1. Introduction  57 
During thyroid-associated ophthalmopathy (TAO) orbital tissues become inflamed and are 58 
remodeled. TAO occurs with a variable presentation: in some patients, extra ocular muscles 59 
(EOM) enlargement predominates, while in others, the connective/adipose tissue enlargement 60 
appears the most significant problem, or both EOM and the connective/adipose tissue are 61 
involved. 62 
The frequency of EOM involvement and diplopia in patients with Graves’ disease (GD) [1] 63 
ranges from 5–10% [2] to 49% of the patients [3]. There is also a minority of patients whose 64 
endocrine orbitopathy consists almost only of involvement of the EOM [4]. 65 
A complex interplay among orbital fibroblasts, myocytes, immune cells, cytokines, 66 
autoantibodies, genetics and environmental factors cause the dramatically enlarged EOM and 67 
increased orbital fat (OF) in TAO [5]. However, clear and indisputable identification of a 68 
target antigen has not been established. In this scenario, autoantibodies specific for fibroblast 69 
surface TSH-receptor (TSH-r) and IGF-1 receptor (IGF-1r) are proposed initiators of orbital 70 
inflammation [5]. Interestingly, TSH-r protein is expressed also in EOM [6]. However, 71 
increased TSH-r and IGF-1r expression occurs with adipogenesis, providing an alternative, 72 
non-causative explanation for their presence in TAO orbits [5, 7]. 73 
The nature and significance of antibodies targeting EOM and orbital connective tissue (OCT) 74 
antigens have also been studied by other studies, suggesting that autoimmunity against the 75 
EOM antigen calsequestrin and the OCT antigen collagen XIII has an important role in the 76 
pathogenesis of TAO [8, 9], or that eye-muscle stimulating antibodies were demonstrable in 77 
sera of patients with TAO [10]. 78 
EOM participate in the pathogenesis of inflammation producing cytokines, whatever the 79 
primary target antigen. In fact, interferon (IFN)γ, tumor necrosis factor (TNF)α, interleukin 80 
(IL)-1beta, and IL-6 mRNA were mainly detected in EOM tissue [11], suggesting that T 81 
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helper (Th)1-like cytokines predominate in EOM tissue in most patients, probably playing a 82 
role on the development of eye muscle component of TAO in the acute stage [12]. 83 
Recent data have shown that C-X-C α-chemokines (Th1), in particular chemokine (C-X-C 84 
motif) ligand (CXCL)9, CXCL10 and CXCL11, play an important role in the initial phases of 85 
autoimmune disorders [13-15]. Serum CXCL10 levels are increased in GD, especially in 86 
patients with active disease, and the CXCL10 decrease after thyroidectomy [16] or after 87 
radioiodine [17] shows that it is more likely to have been produced inside the thyroid gland. 88 
Furthermore, patients with newly diagnosed autoimmune thyroiditis show increased serum 89 
CXCL10, in particular in the presence of a more aggressive thyroiditis and hypothyroidism 90 
[13, 14, 18].  91 
The secretion of CXCL10, CXCL9 and CXCL11 in primary cultures of TAO fibroblasts and 92 
preadipocytes can be stimulated by IFNγ,  and TNFα [19], suggesting that these cells 93 
participate in the self-perpetuation of inflammation by releasing chemokines (under the 94 
influence of cytokines) and inducing the recruitment of activated T cells in the thyroid. The 95 
IFNγ-stimulated C-X-C chemokine secretion was significantly inhibited treating orbital cells 96 
with peroxisome proliferator-activated receptor (PPAR)γ activators, at near-therapeutical 97 
doses, strongly suggesting that PPARγ might be involved in the regulation of IFNγ-induced 98 
chemokine expression in TAO [19]. 99 
Until now, no study has evaluated the chemokines expression in EOM in TAO. We aimed to: 100 
1) compare serum CXCL10 and chemokine [C-C motif ligand (CCL)2] levels in patients with 101 
active TAO (TAO-p) with prevalent EOM involvement (EOM-p) in comparison with those 102 
with prevalent OF expansion (OF-p); 2) test the effect of IFNγ and/or TNFα stimulation on 103 
the secretion of the prototype Th1 (CXCL10), and Th2 (CCL2) chemokines in primary 104 
cultures of orbital EOM myoblasts; 3) assess the effect of PPARγ activation on CXCL10 and 105 
CCL2 secretion in EOM myoblasts. 106 
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 107 
2. Materials and Methods 108 
2.1 In vivo studies 109 
2.1.1 Patients 110 
We selected 26 consecutive Caucasian patients with GD and with active TAO and 26 age- and 111 
sex-matched controls from our outpatient clinic (Table 1). The selection criteria included the 112 
presence of exophthalmos, and: 1) expansion of OF, without evident EOM at orbital 113 
computed tomography (CT); 2) EOM muscle enlargement without OF expansion at CT; 3) all 114 
mixed forms (presence of both, OF expansion and EOM enlargement, were excluded). The 115 
diagnosis of GD was established from the clinical presentation [20].  116 
All TAO-p were clinically euthyroid on antithyroid drugs (16 patients), levo-thyroxine (6 117 
patients) or spontaneously (4 patients), at the time of evaluation and eye disease activity was 118 
assessed by the Clinical Activity Score [20]. A score of 5 (maximal score=10), including a 119 
worsening over the previous 2 months, was considered indicative of active TAO. Inactive eye 120 
disease was defined as no changes in eye status over the previous 6 months. Considering these 121 
26 patients, 21 had never received immunosuppressive therapy, 3 had been previously treated 122 
with corticosteroids, 1 with orbital irradiation, and 1 with both; a median of 11 months (range 123 
6-42) had elapsed from the end of treatment. Total Eye Score was calculated as the sum of the 124 
products of each NOSPECS class by its grade (to this purpose, we substituted 1, 2 and 3, 125 
respectively, for grades a, b and c) [20]. We recorded the duration of both the eye and the 126 
thyroid disease since their first signs and symptoms. 127 
2.1.2 Controls 128 
We enrolled a control group of 26 sex- and age (± 5 years)-matched subjects extracted from a 129 
random sample of the general population from the same geographic area of the patients, in 130 
whom the presence of thyroid disorders was excluded by a complete thyroid work-up [18]. 131 
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A blood sample was collected in the morning after an overnight fasting, and serum was kept 132 
frozen until the measurement of thyroid hormones, thyroid autoantibodies, CXCL10 and 133 
CCL2, in both patients and controls. All study subjects gave their informed consent to 134 
participate in the study, which was approved by the local Ethical Committee. 135 
 136 
2.2 In vitro studies 137 
We investigated the effects of IFNγ, TNFα and PPARγ agonists on the release of CXCL10 138 
and CCL2 in primary cultures of human myoblasts. 139 
2.2.1 Human myoblasts cultures  140 
EOM samples were obtained from 5 patients operated on for EOM repair or decompression 141 
(all previously treated with antithyroid medication and systemic corticosteroids, euthyroid at 142 
the time of surgery; none treated with orbital radiotherapy). Control myoblasts were obtained 143 
from M. rectus abdominis in 5 patients undergoing abdominal surgery. Human skeletal muscle 144 
cells were prepared as previously reported [21].  145 
Cells were isolated from EOM, or M. rectus abdominis, with trypsin followed by a 146 
purification step with fibroblast-specific magnetic beads to prevent contamination with 147 
fibroblasts. After two passages, the myoblasts were characterized by the manufacturer 148 
(PromoCell, VWR International PBI S.r.l., Milan, Italy) using immunohistochemical detection 149 
of sarcomeric myosin in differentiated cultures at 100% confluence (8 days). These cells were 150 
grown to confluence in 25 cm2 flasks, trypsinized, and subsequently 1x106 cells were seeded 151 
in 75 cm2 flasks. After two passages, 5–7.5 x 107 cells were harvested and stored until further 152 
use as frozen aliquots containing 2x106 myoblasts. For each experiment, 105 cells per well 153 
were seeded in six-well culture plates and cultured in α-modified Eagle’s/Ham’s F-12 154 
medium containing Skeletal Muscle Cell Growth Medium Supplement Pack (PromoCell) to 155 
near confluence. The cells were then differentiated and fused by culture in modified Eagle’s 156 
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medium supplemented with 2% fetal calf serum (FCS) for 7 days. The myocytes were 157 
cultured in differentiation medium without FCS for 24 h before being used for any experiment 158 
[21]. 159 
2.2.2 CXCL10 and CCL2 secretion assay  160 
We seeded 3000 cells onto 96-well plates in growth medium and after 24 h the growth 161 
medium was removed and cells were accurately washed in phosphate-buffered saline, and 162 
incubated in phenol red and serum-free medium. Cells were treated with IFNγ (R&D Systems, 163 
Minneapolis, MN, USA; 0, 500, 1000, 5000, 10000 IU/mL) and 10 ng/mL TNFα (R&D 164 
Systems), alone or in combination [19], for 24 h. The concentration of TNFα was selected in 165 
preliminary experiments to yield the highest responses. Then, the supernatant was removed 166 
and frozen at –20°C until assays. 167 
Moreover, cells were stimulated with IFNγ (1000 IU/mL) and TNFα (10 ng/mL) for 24 h in 168 
the absence or presence of increasing concentrations (0, 0.1, 1, 5, 10, 20 µM) of the pure 169 
PPARγ agonists, rosiglitazone (RGZ, GlaxoSmithKline, Brentford, UK), or pioglitazone 170 
(Alexis Biochemicals, Lausen, Switzerland). Conditioned medium was assayed by enzyme-171 
linked immunosorbent assay (ELISA) for CXCL10 and CCL2 concentrations. All 172 
experiments were repeated 3 times with the 10 different cell preparations. 173 
2.2.3 Cell cultures and PPARγ  agonists treatment  174 
Myoblasts were treated with 0.1, 1, 5, 10, or 20 µM RGZ or pioglitazone for 24 h, while 175 
control cultures were grown in the same medium containing vehicle (absolute ethanol, 0.47% 176 
v/v) without RGZ or pioglitazone for 24 h. Some cultures were examined by phase contrast 177 
microscopy by an Olympus IX50 light microscope (New Hyde Park, NY). 178 
For quantitation of total protein in cell preparations, lysis and homogenization were performed 179 
and the sample was assayed for its protein concentration by conventional methods [19].  180 
2.2.4 ELISA for CXCL10 and CCL2 181 
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CXCL10 and CCL2 levels were measured in serum and culture supernatants, by a quantitative 182 
sandwich immunoassay with a commercially available kit (R&D Systems). The mean 183 
minimum detectable dose for CXCL10 was 1.35 pg/mL; the intra- and inter-assay coefficients 184 
of variation were 3.1% and 6.8%. The mean minimum detectable dose for CCL2 was 4.6 185 
pg/mL; the intra- and inter-assay coefficients of variation were 4.6% and 5.7%. Quality 186 
control pools of low, normal, or high concentration for all parameters were included in each 187 
assay. 188 
2.2.5 Reverse transcription-polymerase chain reaction (RT-PCR) for PPARγ  189 
Total RNA from the cells was extracted with the RNeasy Mini reagent kit according to the 190 
manufacturer’s recommendations (QIAGEN S.r.l., Milan, Italy). TaqMan Reverse 191 
Transcription Reagents kit and Universal PCR Master Mix were from Applied Biosystems - 192 
Life Technologies (Grand Island, NY, USA). Quantitative PCR human reference total RNA 193 
was purchased from Stratagene (La Jolla, CA, USA). Primers and probes for PPARγ were 194 
from Applied Biosystems (TaqMan Gene Expression Assay; Hs00234592_m1). Total RNA 195 
(400 ng) was reverse transcribed using TaqMan Reverse Transcription Reagents kit as 196 
reported previously [22]. The amount of target, normalized to the endogenous reference 197 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Pre-Developed TaqMan Assay 198 
Reagents, Applied Biosystems) and relative to a calibrator (Quantitative PCR human 199 
reference total RNA), was given by 2-ΔΔCt calculation [22]. 200 
 201 
2.3 Data analysis 202 
Values are given as mean±standard deviation (SD)  for normally distributed variables, 203 
otherwise as median and [interquartile range]. Mean group values were compared by using 204 
analysis of variance (ANOVA) for normally distributed variables, otherwise by the Mann-205 
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Whitney U or Kruskal-Wallis test. Proportions were compared by the χ2 test. Post-hoc 206 
comparisons of normally distributed variables were performed with the Bonferroni-Dunn test. 207 
 208 
3. Results 209 
3.1 In vivo studies 210 
Serum CXCL10 levels were higher in both OF-p and EOM-p, than in controls (Fig. 1A), 211 
however no significant difference was observed between OF-p and EOM-p. Serum CCL2 212 
levels were not significantly different in controls, or in both OF-p and EOM-p (Fig. 1B).  213 
 214 
3.2 In vitro studies 215 
In primary EOM cell cultures, CXCL10 was undetectable in the supernatant, IFNγ dose-216 
dependently induced its release (Fig. 2A), while TNFα alone had no effect. The combination 217 
of IFNγ (1000 IU/mL) and TNFα (10 ng/mL) had a significant synergistic effect on CXCL10 218 
secretion (2644 ± 114 vs. 205 ± 43 pg/mL with IFNγ alone, P < 0.0001) (Fig. 2B).  219 
PPARγ mRNAs were detectable in all primary EOM cells. PPARγ expression vs. the 220 
reference gene (GAPDH) ranges from 0.39 to 1.11 in EOM cells and from 0.21 to 2.03 in 221 
control muscle cells.  222 
Treating EOM cells with RGZ (Fig. 3A), or pioglitazone (Fig. 3B), in combination with the 223 
IFNγ+TNFα stimulation, dose-dependently inhibited CXCL10 release. RGZ or pioglitazone 224 
alone had no effect and did not affect cell viability or total protein content (data not shown). 225 
Regarding the CXCL10 secretion, the results obtained in muscle cells from M. rectus 226 
abdominis tissue (data not shown) were not statistically different from those obtained in EOM 227 
cells. 228 
In primary EOM cells, CCL2 was detectable in the supernatant, TNFα dose-dependently 229 
induced CCL2 release (Fig. 4A), while IFNγ alone had no effect. The combination of TNFα 230 
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and IFNγ had a significant synergistic effect on CCL2 secretion (2760 ± 247 vs. 611 ± 53 231 
pg/mL with TNFα alone, P < 0.0001) (Fig. 4B).  232 
Treating EOM cells with RGZ (Fig. 5A), or pioglitazone (Fig. 5B), in combination with the 233 
IFNγ+TNFα stimulation, dose-dependently stimulated CCL2 release. 234 
Regarding the CCL2 secretion, the results obtained in muscle cells from M. rectus abdominis 235 
tissue (data not shown) were not statistically different from those obtained in EOM cells. 236 
 237 
4. Discussion 238 
The increased levels of CXCL10 in active TAO agree with previous studies that showed a 239 
predominant involvement of Th1 cytokines in GD and TAO [23, 24]. In fact, it has been 240 
shown that the active phase in TAO is characterized by the presence of proinflammatory and 241 
Th1-derived cytokines, while other cytokines, among them Th2-derived cytokines, do not 242 
seem to be associated with a specific stage of TAO [24]. These results are in agreement with 243 
those observed in a previous study showing that serum CXCL10 levels are increased in TAO-244 
p, especially in patients with active disease [19].  245 
The increase in CXCL10 concentrations was unrelated to hyperthyroidism per se, as all our 246 
patients were clinically euthyroid at the time of the study. CXCL10 levels were similar in OF-247 
p and EOM-p, both in the active phase of the disease, but higher than in normal controls, 248 
suggesting that CXCL10 is involved in the active phase of TAO, during which the 249 
inflammatory process is sustained by Th1-mediated immune responses, independently from 250 
the prevalent involvement of OF or EOM.  251 
A switch from a Th1 to Th2 phenotype appears to occur in TAO, in line with a previous report 252 
showing that lymphocytes obtained from orbital tissue of TAO-p had a prevalent Th1 profile, 253 
whereas patients with remote-onset hyperthyroidism had a large majority of Th2 lymphocytes 254 
[23]. 255 
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This phenomenon has been reported in other long-standing autoimmune diseases. In multiple 256 
sclerosis simultaneous measurements of CXCL10 in the serum and cerebrospinal fluid 257 
showed elevated CXCL10 levels in acute phase, recent-onset disease or during exacerbations, 258 
suggesting a pathogenetic role for the chemokine in mediating relapse [25]. The prognostic 259 
value of increased, or rising, CXCL10 levels in patients with TAO remains to be established.  260 
The difference between active and inactive TAO is the presence of a lymphocytic infiltrate 261 
[26]; therefore the increased production of CXCL10 might be sustained by orbital 262 
lymphocytes. However, our in vitro studies demonstrate that CXCL10 can be produced by 263 
non-lymphoid cells in the orbit. In fact, we have previously shown that both fibroblasts and 264 
preadipocytes from TAO-p secreted CXCL10 stimulated with increasing doses of IFNγ, and 265 
that the combination of IFNγ and TNFα synergistically increased CXCL10 secretion [20].  266 
In this study we first show that EOM cells secrete CXCL10 when stimulated with increasing 267 
doses of IFNγ, and the combination of IFNγ and TNFα synergistically increases CXCL10 268 
secretion. These results agree with previous studies showing that the idiopathic inflammatory 269 
myopathies (dermatomyositis, polymyositis and sporadic inclusion body myositis) are 270 
associated with CXCL10 upregulation [27]. A significant increase in CXCL10 and chemokine 271 
(C-X-C motif) receptor (CXCR)3 mRNA levels in both thymus and muscle was observed also 272 
in myasthenic patients [28]. Moreover, another study reported that IFNγ upregulated the 273 
mRNA expression of CXCL9 and CXCL10 by human myotubes in a dose-dependent manner 274 
[29]. It has been also recently shown that human fetal cardiomyocytes secreted CXCL10 in 275 
response to IFNγ and TNFα, and that this effect was magnified by cytokine combination [30]. 276 
Different types of normal mammalian cells, as endothelial cells, thyrocytes [20], fibroblasts 277 
[20], and others, can release IFNγ-inducible C-X-C chemokines. However, these cells do not 278 
produce the C-X-C chemokines in basal condition, but only after the stimulation by cytokines, 279 
such as IFNγ and TNFα, that are secreted in a Th1 type inflammatory site, such as the orbit at 280 
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the beginning of TAO, by Th1 activated lymphocytes. This process has been suggested to be 281 
involved in the initiation and the perpetuation of the inflammation in several autoimmune 282 
diseases, and on the basis of our results can be applied to the orbit in TAO, too. 283 
IFNγ stimulated EOM to express human leukocyte antigen (HLA)-DR. EOM cells treated 284 
with IFNγ were more susceptible to lysis in antibody dependent cell-mediated cytotoxicity 285 
assays than untreated targets [31]. It could be hypothesized that chemokines might be 286 
important in the above mentioned immune process. 287 
PPARγ modulate inflammatory responses in many kinds of cells: endothelial cells, thyrocytes, 288 
fibroblasts, preadipocytes [17, 19, 32], and in others. Furthermore, the role of PPARγ has been 289 
shown to be of importance in TAO; in fact, the IFNγ-stimulated CXCL9, CXCL10 and 290 
CXCL11 [19, 20, 22] secretion was significantly inhibited treating thyroid follicular cells, 291 
orbital fibroblasts or preadipocytes with a pure PPARγ activator, RGZ, strongly suggesting 292 
that PPARγ might be involved in the regulation of IFNγ-induced chemokine expression in 293 
human thyroid autoimmunity and TAO. 294 
In this study we have shown the expression of PPARγ in EOM cells. Furthermore, the results 295 
of our study are the first to demonstrate that the IFNγ-stimulated CXCL10 secretion was 296 
significantly inhibited by the treatment of EOM with two pure PPARγ activators, RGZ and 297 
pioglitazone. The drug concentrations were selected on the basis of their near therapy doses (5 298 
µM for RGZ and pioglitazone) according to their pharmacokinetics (Cmax and area under the 299 
time-concentration curve, AUC) [19]. These results strongly reinforce the hypothesis that 300 
PPARγ might be involved in the regulation of the IFNγ-induced chemokine expression in 301 
human thyroid autoimmunity and TAO. 302 
Regarding the mechanism of these actions, PPARγ activators may act in different way. For 303 
example, by decreasing CXCL10 promoter activity and inhibiting protein binding to the two 304 
nuclear factor-kB (NF-kB) sites [17, 19], or reducing CXCL10 protein levels in a dose-305 
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dependent manner at concentrations (nanomolar) that did not affect mRNA levels or NF-kB 306 
activation. This effect is not only mediated by activating the NF-kB and Stat1 classic 307 
pathways, but also involves a rapid increase in phosphorylation and activation of ERK1/2 308 
[33]. 309 
The role of CCL2 in TAO is not yet completely clear. A first study showed that the expression 310 
of CCL2 was higher in orbital fat of TAO patients than in controls [34]. The expression of 311 
CCL2 in TAO fibroblasts was upregulated treating cells with CD154, the ligand for CD40, 312 
which failed to do so in control cultures [35]. Moreover, CCL2 production by orbital 313 
fibroblasts was increased by platelet-derived growth factor-BB stimulation [36]. To the best of 314 
our knowledge, this study first shows that IFNγ and TNFα induce CCL2 secretion in EOM 315 
cells. These results comply with the ones of previous studies in skeletal muscle cells, that 316 
showed that IFNγ and TNFα were able to induce CCL2 secretion [37], which was involved in 317 
the immune response in idiopathic inflammatory myopathies [27]. 318 
PPARγ activators have been shown to be able to suppress CCL2 expression in various cell 319 
types, such as astrocytes and monocytes, via different pathways (mitogen-activated protein 320 
kinase phosphatase-1, Toll-like receptor) [38, 39]. However, until now, no study has evaluated 321 
the effect of PPARγ agonists on CCL2 secretion in skeletal and EOM muscles. Moreover, we 322 
have recently shown that PPARγ agonists may have different effects in normal thyroid cells 323 
(inhibiting CXCL10 secretion), or in papillary thyroid cancer cells (stimulating CXCL10), 324 
suggesting that other pathways could be implicated in the PPARγ regulation of chemokine 325 
secretion, that remain to be investigated [40]. According to our data, it could be hypothesized 326 
that PPARγ agonists (that have an inhibitory role on the secretion of the Th1 CXCL10 327 
chemokine, while stimulated the Th2 CCL2 chemokine) may be involved during the 328 
progression of the disease in the switch from a prevalent Th1 immune response, in the first 329 
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phase of the disease, to a prevalent Th2 immunity, in the later phases. However, other studies 330 
are needed to evaluate this point. 331 
Recently, it has been shown that RGZ was associated with an increased risk of stroke, heart 332 
failure, and all-cause mortality in elderly patients [41], and the European Medicines Agency 333 
(EMA) recommended on September 2010 that RGZ be suspended from the European market. 334 
More recently, EMA extended review of safety to pioglitazone [42]. Even if these arguments 335 
cannot be automatically translated in TAO field, they do not advice PPARγ agonists for the 336 
therapy of TAO. 337 
 338 
In conclusion, CXCL10 serum levels were confirmed to be higher than in control subjects in 339 
the active phase of TAO, without any significant difference between OF-p and EOM-p. 340 
Moreover, the present study first shows that primary EOM cells from patients with TAO 341 
produce both Th1 (CXCL10) and Th2 (CCL2) chemokines, under the influence of IFNγ 342 
and/or TNFα, and may participate in the inflammatory process present in the orbit of patients 343 
with TAO. PPARγ expression has been shown in EOM cells and PPARγ agonists have an 344 
inhibitory role on the modulation of CXCL10, while stimulated CCL2 chemokine secretion, 345 
suggesting a possible role in the switch from Th1 to Th2 immunity. 346 
 347 
Take-home messages:  348 
 349 
• We demonstrate elevated serum CXCL10 levels in the active phase of  TAO   350 
• Primary EOM cells, of TAO patients, treated with IFNγ and TNFα, release chemokines  351 
• We have shown the PPARγ expression in EOM cells    352 
• PPARγ agonists inhibit CXCL10, but stimulate CCL2, in EOM  353 
• EOM cells are involved in the inflammatory process in the orbit of TAO patients     354 
355 
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Table 1. Characteristics of patients with active Graves’ ophthalmopathy: patients with 502 
prevalent orbital fat expansion (OF), or with prevalent extra-ocular muscle (EOM) 503 
involvement. 504 
  
OF 
 
EOM 
 
P 
 
n 
 
16 
 
10 
 
 
Sex (M/F) 
 
4/12 
 
3/7 
 
ns 
 
Age (years) 
 
40 ± 10 
 
36 ± 12 
 
ns 
 
Smoking (no/yes) 
 
7/9 
 
5/5 
 
ns 
 
Duration GO (months) 
 
7 (1-32) 
 
5 (1-29) 
 
0.001 
 
Duration thyroid disease (months) 
 
8 (2-39) 
 
8 (1-44) 
 
0.001 
 
TSH (mIU/L) 
 
1.1 ± 2.4 
 
1.4 ± 1.3 
 
ns 
 
Free T3 (FT3) pg/mL (pmol/L) 
 
3.7 ± 2.3 
(5.7 ± 3.5)  
 
3.9 ± 2.2 
(6 ± 3.4) 
 
ns 
 
Free T4 (FT4) ng/dL (pmol/L) 
 
1.4 ± 0.9 
(18 ± 11.6) 
 
1.2 ± 1.5 
(15.4 ± 19.3) 
 
ns 
 
Anti-thyroid peroxidase antibodies    
(AbTPO) (kIU/L) 
 
342 ± 276 
 
297 ± 314 
 
ns 
 
Anti-thyroglobulin antibodies 
(AbTg) (kIU/L) 
 
325 ± 529 
 
187 ± 372 
 
ns 
 
Anti-thyrotropin receptor 
autoantibodies (TRAb) (kIU/L) 
 
21 ± 42 
 
32 ± 39 
 
ns 
 
Past immunosuppression (no/yes) 
 
13/3 
 
9/1 
 
ns 
 
Clinical Activity Score 
 
5.3 ± 1.9 
 
6.7 ± 1.6 
 
ns 
 
Total Eye Score 
 
 
23.0 ± 7.2  
 
25.4 ± 8.7 
 
ns 
505 
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Figure Captions 505 
Figure 1. Serum CXCL10 and CCL2 levels in patients with active GO or controls. Serum 506 
CXCL10 levels were higher in both patients with active GO with prevalent OF expansion (OF 507 
patients) and with prevalent EOM involvement (EOM patients) than in controls (P < 0.01, 508 
ANOVA, for both) (A), however no significant difference was observed between OF patients 509 
and EOM patients. Serum CCL2 levels were not significantly different in controls, or in both 510 
OF patients and EOM patients (B). The box indicates the lower and upper quartiles and the 511 
central line is the median value; the horizontal lines at the end of the vertical lines are the 512 
2.5% and 97.5% values. * = P < 0.05 or less vs. controls by Bonferroni-Dunn test. 513 
 514 
Figure 2. Stimulation of CXCL10 release from EOM cells by IFNγ (1000 IU/mL) and TNFα 515 
(10 ng/mL). CXCL10 release from EOM cells was absent under basal conditions (0) and was 516 
significantly stimulated by increasing doses of IFNγ (P < 0.0001, by ANOVA) (A). Bars are 517 
mean±SEM. * = P < 0.05 or less vs. 0 by Bonferroni-Dunn test. The combination of TNFα 518 
and IFNγ had a significant synergistic effect on CXCL10 secretion (* = P < 0.0001, by 519 
ANOVA) (B). 520 
 521 
Figure 3. CXCL10 secretion from EOM cells treated with rosiglitazone or pioglitazone. 522 
Treatment of EOM cells with rosiglitazone (A), or pioglitazone (B), added at the time of IFNγ 523 
(1000 IU/mL) and TNFα (10 ng/mL) stimulation, dose-dependently inhibited CXCL10 524 
release. Bars are mean±SEM. * = P < 0.05 or less vs. 0, and ° = not significantly different 525 
from the preceding dose by Bonferroni-Dunn test. 526 
 527 
Figure 4. Stimulation of CCL2 release from EOM cells by IFNγ (1000 IU/mL) and TNFα (10 528 
ng/mL). CCL2 release from EOM cells was present under basal conditions (0) and was 529 
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significantly stimulated by increasing doses of TNFα (P < 0.0001, by ANOVA) (A). Bars are 530 
mean±SEM. * = P < 0.05 or less vs. 0 by Bonferroni-Dunn test. The combination of TNFα 531 
and IFNγ had a significant synergistic effect on CCL2 secretion (B). * = P < 0.05 or less vs. 532 
IFNγ or TNFα by Bonferroni-Dunn test; ° = P < 0.05 or less vs. IFNγ by Bonferroni-Dunn 533 
test.  534 
 535 
Figure 5. CCL2 secretion from EOM cells treated with rosiglitazone or pioglitazone. 536 
Treatment of EOM cells with rosiglitazone (A), or pioglitazone (B), added at the time of IFNγ 537 
(1000 IU/mL) and TNFα (10 ng/mL) stimulation, dose-dependently stimulated CCL2 release. 538 
Bars are mean±SEM. * = P < 0.05 or less vs. 0, and ° = not significantly different from the 539 
preceding dose by Bonferroni-Dunn test. 540 
541 
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Take-home messages:  541 
 542 
• We demonstrate elevated serum CXCL10 levels in the active phase of  TAO   543 
• Primary EOM cells, of TAO patients, treated with IFNγ and TNFα, release chemokines  544 
• We have shown the PPARγ expression in EOM cells    545 
• PPARγ agonists inhibit CXCL10, but stimulate CCL2, in EOM  546 
• EOM cells are involved in the inflammatory process in the orbit of TAO patients     547 
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